Abstract
Esketamine, which is an S-enantiomer of ketamine, is better than conventional antidepressants and even better than R-ketamine. This article discusses the mechanism of action of Esketamine, how different it is from other antidepressants, its side effect profile, indications for use, various routes of administration and the review of existing literature on Esketamine.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not Applicable.
-
Ethical approval: Not applicable.
References
1. Bahr, R, Lopez, A, Rey, JA. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T 2019;44:340–75.Search in Google Scholar
2. Murrough, JW. Ketamine for depression: an update. Biol Psychiatr 2016;80:416–8. https://doi.org/10.1016/j.biopsych.2016.07.005.Search in Google Scholar PubMed
3. Molero, P, Ramos-Quiroga, JA, Martin-Santos, R, Calvo-Sánchez, E, Gutiérrez-Rojas, L, Meana, JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 2018;32:411–20. https://doi.org/10.1007/s40263-018-0519-3.Search in Google Scholar PubMed
4. Turner, EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatr 2019;6:977–9. https://doi.org/10.1016/s2215-0366(19)30394-3.Search in Google Scholar PubMed
5. Salahudeen, MS, Wright, CM, Peterson, GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf 2020;11:2042098620937899. https://doi.org/10.1177/2042098620937899.Search in Google Scholar PubMed PubMed Central
6. Yang, C, Ren, Q, Qu, Y, Zhang, JC, Ma, M, Dong, C, et al.. Mechanistic target of rapamycin-independent antidepressant effects of (R)-Ketamine in a social defeat stress model. Biol Psychiatr 2018;83:18–28. https://doi.org/10.1016/j.biopsych.2017.05.016.Search in Google Scholar PubMed
7. Paul, R, Schaaff, N, Padberg, F, Möller, HJ, Frodl, T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatr 2009;10:241–4. https://doi.org/10.1080/15622970701714370.Search in Google Scholar PubMed
8. Correia-Melo, FS, Leal, GC, Vieira, F, Jesus-Nunes, AP, Mello, RP, Magnavita, G, et al.. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord 2020;264:527–34. https://doi.org/10.1016/j.jad.2019.11.086.Search in Google Scholar PubMed
9. Singh, JB, Fedgchin, M, Daly, E, Xi, L, Melman, C, Bruecker, GD, et al.. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatr 2016;80:424–31. https://doi.org/10.1016/j.biopsych.2015.10.018.Search in Google Scholar PubMed
10. Kaur, U, Pathak, BK, Singh, A, Chakrabarti, SS. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatr Clin Neurosci 2021;271:417–29. https://doi.org/10.1007/s00406-019-01084-z.Search in Google Scholar PubMed
11. Mihaljević, S, Pavlović, M, Reiner, K, Ćaćić, M. Therapeutic mechanisms of ketamine. Psychiatr Danub 2020;32:325–33. https://doi.org/10.24869/psyd.2020.325.Search in Google Scholar PubMed
12. Janssenlable. Spravato (esketamine) Nasal Spray [Internet]; 2020. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf [Accessed 17 Jul 2021].Search in Google Scholar
13. Daly, EJ, Singh, JB, Fedgchin, M, Cooper, K, Lim, P, Shelton, RC, et al.. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr 2018;75:139–48. https://doi.org/10.1001/jamapsychiatry.2017.3739.Search in Google Scholar PubMed PubMed Central
14. Findeis, H, Sauer, C, Cleare, A, Bauer, M, Ritter, P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology (Berl) 2020;237:3295–302. https://doi.org/10.1007/s00213-020-05611-y.Search in Google Scholar PubMed PubMed Central
15. Katz, EG, Hough, D, Doherty, T, Lane, R, Singh, J, Levitan, B. Benefit-risk assessment of esketamine nasal spray vs. Placebo in treatment-resistant depression. Clin Pharmacol Ther 2021;109:536–46. https://doi.org/10.1002/cpt.2024.Search in Google Scholar PubMed PubMed Central
16. Popova, V, Daly, EJ, Trivedi, M, Cooper, K, Lane, R, Lim, P, et al.. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatr 2019;176:428–38. https://doi.org/10.1176/appi.ajp.2019.19020172.Search in Google Scholar PubMed
17. Doherty, T, Wajs, E, Melkote, R, Miller, J, Singh, JB, Weber, MA. Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program. CNS Drugs 2020;34:299–310. https://doi.org/10.1007/s40263-020-00699-4.Search in Google Scholar PubMed PubMed Central
18. Khorassani, F, Talreja, O. Intranasal esketamine: a novel drug for treatment-resistant depression. Am J Health Syst Pharm 2020;77:1382–8. https://doi.org/10.1093/ajhp/zxaa191.Search in Google Scholar PubMed
19. Canuso, CM, Singh, JB, Fedgchin, M, Alphs, L, Lane, R, Lim, P, et al.. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatr 2018;175:620–30. https://doi.org/10.1176/appi.ajp.2018.17060720.Search in Google Scholar PubMed
20. Kim, J, Farchione, T, Potter, A, Chen, Q, Temple, R. Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class. N Engl J Med 2019;381:1–4. https://doi.org/10.1056/nejmp1903305.Search in Google Scholar PubMed
21. Ionescu, DF, Fu, DJ, Qiu, X, Lane, R, Lim, P, Kasper, S, et al.. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol 2021;24:22–31. https://doi.org/10.1093/ijnp/pyaa068.Search in Google Scholar PubMed PubMed Central
22. Morrison, RL, Fedgchin, M, Singh, J, Van Gerven, J, Zuiker, R, Lim, KS, et al.. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl) 2018;235:1107–19. https://doi.org/10.1007/s00213-018-4828-5.Search in Google Scholar PubMed PubMed Central
23. Wang, J, Wang, Y, Xu, X, Peng, S, Xu, F, Liu, P. Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Med Sci Monit 2020;26:e922028-1–6.10.12659/MSM.922028Search in Google Scholar PubMed PubMed Central
24. Smith-Apeldoorn, SY, Veraart, JKE, Kamphuis, J, van Asselt, ADI, Touw, DJ, Aan Het Rot, M, et al.. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatr 2019;19:375. https://doi.org/10.1186/s12888-019-2359-1.Search in Google Scholar PubMed PubMed Central
25. Bahji, A, Vazquez, GH, Zarate, CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021;278:542–55. https://doi.org/10.1016/j.jad.2020.09.071.Search in Google Scholar PubMed PubMed Central
26. Courtenay, AJ, McAlister, E, McCrudden, MTC, Vora, L, Steiner, L, Levin, G, et al.. Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery. J Contr Release 2020;322:177–86. https://doi.org/10.1016/j.jconrel.2020.03.026.Search in Google Scholar PubMed PubMed Central
27. Fedgchin, M, Trivedi, M, Daly, EJ, Melkote, R, Lane, R, Lim, P, et al.. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 2019;22:616–30. https://doi.org/10.1093/ijnp/pyz039.Search in Google Scholar PubMed PubMed Central
28. McIntyre, RS, Carvalho, IP, Lui, LMW, Majeed, A, Masand, PS, Gill, H, et al.. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord 2020;276:576–84. https://doi.org/10.1016/j.jad.2020.06.050.Search in Google Scholar PubMed
29. McGirr, A, Berlim, MT, Bond, DJ, Neufeld, NH, Chan, PY, Yatham, LN, et al.. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res 2015;62:23–30. https://doi.org/10.1016/j.jpsychires.2015.01.003.Search in Google Scholar PubMed
30. Fu, DJ, Ionescu, DF, Li, X, Lane, R, Lim, P, Sanacora, G, et al.. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatr 2020;81:0.10.4088/JCP.19m13191Search in Google Scholar PubMed
31. Pereira, S, Brennan, E, Patel, A, Moran, M, Wallier, J, Liebowitz, MR. Managing dissociative symptoms following the use of esketamine nasal spray: a case report. Int Clin Psychopharmacol 2021;36:54–7. https://doi.org/10.1097/yic.0000000000000327.Search in Google Scholar PubMed PubMed Central
32. Daly, EJ, Trivedi, MH, Janik, A, Li, H, Zhang, Y, Li, X, et al.. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr 2019;76:893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189.Search in Google Scholar PubMed PubMed Central
33. Jonkman, K, van Rijnsoever, E, Olofsen, E, Aarts, L, Sarton, E, van Velzen, M, et al.. Esketamine counters opioid-induced respiratory depression. Br J Anaesth 2018;120:1117–27. https://doi.org/10.1016/j.bja.2018.02.021.Search in Google Scholar PubMed
© 2022 Walter de Gruyter GmbH, Berlin/Boston
